Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Interest Expenses (2024 - 2025)

Allogene Therapeutics' Interest Expenses history spans 2 years, with the latest figure at $344000.0 for Q3 2025.

  • For Q3 2025, Interest Expenses rose 244.0% year-over-year to $344000.0; the TTM value through Sep 2025 reached $843000.0, up 743.0%, while the annual FY2024 figure was $181000.0, N/A changed from the prior year.
  • Interest Expenses for Q3 2025 was $344000.0 at Allogene Therapeutics, up from $268000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $344000.0 in Q3 2025 and bottomed at $81000.0 in Q4 2024.